Luis Fayad

1.8k total citations
33 papers, 597 citations indexed

About

Luis Fayad is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Luis Fayad has authored 33 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pathology and Forensic Medicine, 17 papers in Genetics and 13 papers in Oncology. Recurrent topics in Luis Fayad's work include Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (17 papers) and CAR-T cell therapy research (6 papers). Luis Fayad is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Chronic Lymphocytic Leukemia Research (17 papers) and CAR-T cell therapy research (6 papers). Luis Fayad collaborates with scholars based in United States, Australia and Singapore. Luis Fayad's co-authors include Susan O’Brien, Michael J. Keating, Razelle Kurzrock, Bang‐Ning Lee, James M. Reuben, Susan Lerner, Peter McLaughlin, Barbara Pro, Farzaneh Maadani and Michèle L. Donato and has published in prestigious journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Luis Fayad

32 papers receiving 584 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luis Fayad United States	11	336	275	227	185	123	33	597
Gérard Buchonnet France	15	336 1.0×	229 0.8×	228 1.0×	128 0.7×	133 1.1×	27	566
Francesco Gaudio Italy	13	349 1.0×	270 1.0×	112 0.5×	204 1.1×	201 1.6×	53	676
Mauro Spriano Italy	18	340 1.0×	230 0.8×	421 1.9×	215 1.2×	211 1.7×	50	712
Ken Ohmachi Japan	13	403 1.2×	342 1.2×	211 0.9×	91 0.5×	87 0.7×	46	599
Minoru Kojima Japan	14	354 1.1×	318 1.2×	176 0.8×	128 0.7×	104 0.8×	42	623
Alison N. Gencarelli United States	6	431 1.3×	235 0.9×	307 1.4×	124 0.7×	82 0.7×	7	532
Antonio Léon Spain	8	402 1.2×	317 1.2×	127 0.6×	187 1.0×	121 1.0×	8	615
JL Huret France	6	301 0.9×	166 0.6×	128 0.6×	91 0.5×	154 1.3×	100	521
Jean‐Marc Schiano de Colella France	13	263 0.8×	261 0.9×	99 0.4×	194 1.0×	145 1.2×	41	600
Therese White United States	11	229 0.7×	195 0.7×	169 0.7×	171 0.9×	98 0.8×	22	557

Countries citing papers authored by Luis Fayad

Since Specialization

Citations

This map shows the geographic impact of Luis Fayad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Fayad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Fayad more than expected).

Fields of papers citing papers by Luis Fayad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Fayad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Fayad. The network helps show where Luis Fayad may publish in the future.

Co-authorship network of co-authors of Luis Fayad

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Fayad. A scholar is included among the top collaborators of Luis Fayad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Fayad. Luis Fayad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Steiner, Raphaël, Paolo Strati, Christopher R. Flowers, et al.. (2022). Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma.. Journal of Clinical Oncology. 40(16_suppl). TPS7589–TPS7589.

Li, Xubin, Qing Deng, Jared Henderson, et al.. (2022). Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. Blood. 140(Supplement 1). 4502–4503. 6 indexed citations

Steiner, Raphaël, Paolo Strati, Christopher R. Flowers, et al.. (2021). Pacific: A Phase II Study of Brentuximab Vedotin and Nivolumab Alone and then Combined with Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Patients with Untreated Primary Mediastinal Large B-Cell Lymphoma. Blood. 138(Supplement 1). 1408–1408. 1 indexed citations

Strati, Paolo, Sherry Adkins, Loretta J. Nastoupil, et al.. (2019). Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma.. Journal of Clinical Oncology. 37(15_suppl). 7545–7545. 8 indexed citations

Anand, Kartik, Ethan Burns, Sai Ravi Pingali, et al.. (2019). Comprehensive report of anti-CD19 chimeric antigen receptor T cells (CAR-T) associated non-relapse mortality (CART-NRM) from FAERS.. Journal of Clinical Oncology. 37(15_suppl). 2540–2540. 3 indexed citations

Chihara, Dai, Yasuhiro Oki, Michelle A. Fanale, et al.. (2018). Stage I Non‐Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement. British Journal of Haematology. 185(2). 334–338. 8 indexed citations

Karuturi, Meghan, Anas Younes, Luis Fayad, et al.. (2015). Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial. Leukemia & lymphoma. 57(2). 445–447. 7 indexed citations

Shah, Nina, Fernando Cabanillas, Bradley W. McIntyre, et al.. (2011). Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leukemia & lymphoma. 53(1). 50–56. 24 indexed citations

Badoux, Xavier C., Alessandra Ferrajoli, William G. Wierda, et al.. (2010). Phase II Study of Dasatinib In Patients with Relapsed Chronic Lymphocytic Leukemia.. Blood. 116(21). 4488–4488. 5 indexed citations

10.

Jones, Dan, et al.. (2009). Differential JAK-STAT Pathway Activation in Primary Mediastinal Large B-Cell Lymphoma: Two Subgroups with Differential Cytokine Activation Patterns and Predicted Responses to Kinase Inhibitors.. Blood. 114(22). 968–968. 1 indexed citations

11.

Thomas, Deborah A., Hagop M. Kantarjian, Jörge E. Cortes, et al.. (2008). Long-Term Outcome after Hyper-CVAD and Rituximab Chemoimmunotherapy for Burkitt (BL) or Burkitt-Like (BLL) Leukemia/Lymphoma and Mature B-Cell Acute Lymphocytic Leukemia (ALL).. Blood. 112(11). 1929–1929. 1 indexed citations

12.

Lim, Soon Thye, Luis Fayad, Anil Tulpule, et al.. (2007). A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leukemia & lymphoma. 48(2). 374–380. 23 indexed citations

13.

Fayad, Luis, Catriona Byrne, Raymond A. Knight, et al.. (2007). A phase I/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. Journal of Clinical Oncology. 25(18_suppl). 8030–8030. 18 indexed citations

14.

Kornblau, Steven M., Stefan Faderl, Miloslav Beran, et al.. (2006). A phase 1 trial of a novel organic arsenic S-dimethylarsino-glutathione (ZIO-101) in hematological malignancies. Journal of Clinical Oncology. 24(18_suppl). 16503–16503. 4 indexed citations

15.

Pro, Barbara, Luis Fayad, Peter McLaughlin, et al.. (2006). Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Leukemia & lymphoma. 47(3). 481–485. 10 indexed citations

16.

Fayad, Luis & Jimena Cannata. (2006). Adult Langerhans’ Cell Histiocitosis (LCH). A Single Institution Experience.. Blood. 108(11). 3890–3890. 1 indexed citations

17.

Eder, Joseph P., S. Anthony, Paul Conkling, et al.. (2006). 139 POSTER Phase I dose escalation safety/tolerance study of PPl-2458 in subjects with Non-Hodgkin's lymphoma or solid tumors. European Journal of Cancer Supplements. 4(12). 45–45. 1 indexed citations

18.

Goy, André, Ahmed Younes, Peter McLaughlin, et al.. (2004). Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL). Journal of Clinical Oncology. 22(14_suppl). 6581–6581. 2 indexed citations

19.

Rodriguez, Maria Alma, Luis Fayad, André Goy, et al.. (2004). Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study. Journal of Clinical Oncology. 22(14_suppl). 8080–8080. 3 indexed citations

20.

Cortes, Jörge E., Luis Fayad, Susan O’Brien, Michael J. Keating, & Hagop M. Kantarjian. (1999). Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity.. PubMed. 5(9). 2491–7. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact